Jazz Pharmaceuticals Statistics
Jazz Pharmaceuticals (J7Z) Stock Statistics & Valuation Metrics
Total Valuation
Jazz Pharmaceuticals has a market cap or net worth of EUR 13.43B. The enterprise value is EUR 17.77B.
- Market Cap
- EUR 13.43B
- Enterprise Value
- EUR 17.77B
Share Statistics
Jazz Pharmaceuticals has 64,189,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 64,189,050
- Owned by Insiders
- 3.34%
- Owned by Institutions
- 70.97%
Financial Efficiency
Jazz Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1.22%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.03
- Return on Invested Capital (ROIC)
- 1.22%
- Return on Capital Employed (ROCE)
- 0.02
- Revenue Per Employee
- 1.48M
- Profits Per Employee
- -123.23K
- Employee Count
- 2,890
- Asset Turnover
- 0.37
- Inventory Turnover
- 1.21
Valuation Ratios
The current PE Ratio of Jazz Pharmaceuticals is 68.56. Jazz Pharmaceuticals’s PEG ratio is 0.04.
- PE Ratio
- 68.56
- PS Ratio
- 3.34
- PB Ratio
- 3.79
- Price to FCF
- 10.02
- Price to Operating Cash Flow
- 9.38
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, Jazz Pharmaceuticals had revenue of 4.27B and earned -356.15M in profits. Earnings per share was -5.84.
- Revenue
- 4.27B
- Gross Profit
- 3.76B
- Operating Income
- 224.42M
- Pretax Income
- -628.59M
- Net Income
- -356.15M
- EBITDA
- 262.76M
- Earnings Per Share (EPS)
- -5.84
Cash Flow
In the last 12 months, operating cash flow was 1.69B and capital expenditures -119.73M, giving a free cash flow of 1.57B billion.
- Operating Cash Flow
- 1.69B
- Free Cash Flow
- 1.57B
- Free Cash Flow per Share
- 24.31
Dividends & Yields
Jazz Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 10.12%
- Earnings Yield
- 1.32%
Stock Price Statistics
- Beta
- 0.44
- 52-Week Price Change
- 82.37%
- 50-Day Moving Average
- 202.33
- 200-Day Moving Average
- 190.33
- Relative Strength Index (RSI)
- 64.98
- Average Volume (3m)
- 21
Important Dates
Jazz Pharmaceuticals upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Jazz Pharmaceuticals as a current ratio of 1.86, with Debt / Equity ratio of 125.59%
- Current Ratio
- 1.86
- Quick Ratio
- 1.67
- Debt to Market Cap
- 0.52
- Net Debt to EBITDA
- 15.34
- Interest Coverage Ratio
- 1.15
Taxes
In the past 12 months, Jazz Pharmaceuticals has paid -272.44M in taxes.
- Income Tax
- -272.44M
- Effective Tax Rate
- 0.43
Enterprise Valuation
Jazz Pharmaceuticals EV to EBITDA ratio is 16.37, with an EV/FCF ratio of 12.17.
- EV to Sales
- 4.06
- EV to EBITDA
- 16.37
- EV to Free Cash Flow
- 12.17
- EV to Operating Cash Flow
- 11.31
Balance Sheet
Jazz Pharmaceuticals has EUR 2.86B in cash and marketable securities with EUR 5.64B in debt, giving a net cash position of -EUR 2.79B billion.
- Cash & Marketable Securities
- EUR 2.86B
- Total Debt
- EUR 5.64B
- Net Cash
- -EUR 2.79B
- Net Cash Per Share
- -EUR 43.44
- Tangible Book Value Per Share
- -EUR 27.58
Margins
Gross margin is 88.17%, with operating margin of 20.30%, and net profit margin of 4.37%.
- Gross Margin
- 88.17%
- Operating Margin
- 20.30%
- Pretax Margin
- 5.50%
- Net Profit Margin
- 4.37%
- EBITDA Margin
- 24.79%
- EBIT Margin
- 9.56%
Analyst Forecast
The average price target for Jazz Pharmaceuticals is EUR 270.68, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 270.68
- Price Target Upside
- 27.68% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 17
- Revenue Growth Forecast
- 8.06%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 8
- AI Score
- ―
